Loading…
Polyrizon Ltd.
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
None of the investors we track reported a position in PLRZ.
▼ -99.5% over 5Y.
This stock has less than 5 years of price history — the answer would measure a shorter period than the one asked for.
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 2 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 |
|---|---|---|---|
| Year-end price | $8.49 | $3,255.00 | |
| P/E | — | 1.7x | 4.0x |
| P/B | — | 0.7x | 1.7x |
| EPS | $4.90 | $805.20 | |
| ROE | — | -15.89% | -29.23% |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| BYSIBeyondSpring Inc. | $0.67 | — | — | — | — | $27.36M |
| CVMCel Sci Corp | $1.56 | — | 2.5x | — | -252.53% | $27.44M |
| ARAYAccuray Inc | $0.23 | — | 0.6x | — | -80.08% | $26.93M |
| FEMYFemasys Inc | $3.20 | — |
Polyrizon Ltd., a biotech company, engages in the development of medical device hydrogels in the form of nasal sprays in Israel. The company uses its proprietary technology to develop its products comprising Capture and Contain, a barrier against a range of allergen particulates and viruses; and Trap and Target for nasal delivery of active pharmaceutical ingredients. It also develops PL-14, a nasal allergies blocker; and PL-16 for influenza blockers. Polyrizon Ltd. was incorporated in 2005 is headquartered in Ra'anana, Israel.
Company description provided by Yahoo Finance.
| 2.4x |
| — |
| -424.97% |
| $26.8M |
| OPTHOptimi Health Corp. | $4.93 | — | 2.2x | — | -54.36% | $28.2M |
| MODDModular Medical, Inc. | $3.46 | — | 1.2x | — | -247.94% | $28.2M |